The future of cystic fibrosis care: a global perspective

SC Bell, MA Mall, H Gutierrez, M Macek… - The Lancet …, 2020 - thelancet.com
Executive summary The past six decades have seen remarkable improvements in health
outcomes for people with cystic fibrosis, which was once a fatal disease of infants and young …

A guide to therapeutic drug monitoring of β‐lactam antibiotics

AJ Fratoni, DP Nicolau, JL Kuti - Pharmacotherapy: The Journal …, 2021 - Wiley Online Library
Therapeutic drug monitoring (TDM) opens the door to personalized medicine, yet it is
infrequently applied to β‐lactam antibiotics, one of the most commonly prescribed drug …

[HTML][HTML] Airway commensal bacteria in cystic fibrosis inhibit the growth of P. aeruginosa via a released metabolite

A Tony-Odigie, AH Dalpke, S Boutin, B Yi - Microbiological research, 2024 - Elsevier
In cystic fibrosis (CF), Pseudomonas aeruginosa infection plays a critical role in disease
progression. Although multiple studies suggest that airway commensals might be able to …

[HTML][HTML] International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core …

JK Marthin, JS Lucas, M Boon, C Casaulta… - ERJ open …, 2021 - Eur Respiratory Soc
Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to
recurrent airway infections and progressive lung destruction, and concern over chronic …

Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis

NJ Rowbotham, SJ Smith, ZC Elliott… - Research Involvement …, 2019 - Springer
Plain English summary Cystic fibrosis (CF) is the commonest life-limiting inherited disorder
in the UK. It affects many parts of the body including the lungs and gut leading to increased …

[HTML][HTML] Hope in every breath: navigating the therapeutic landscape of cystic fibrosis

H Sreenivasulu, S kumar Muppalla, S Vuppalapati… - Cureus, 2023 - ncbi.nlm.nih.gov
Cystic fibrosis (CF) has long posed a complex challenge to medical science. Still, the tides
are turning with remarkable progress in prognosis and demographics, thanks to cutting …

[HTML][HTML] α-Tocopherol pharmacokinetics in adults with cystic fibrosis: benefits of supplemental vitamin C administration

MG Traber, SW Leonard, VT Vasu, BM Morrissey… - Nutrients, 2022 - mdpi.com
Background: Numerous abnormalities in cystic fibrosis (CF) could influence tocopherol
absorption, transportation, storage, metabolism and excretion. We hypothesized that the …

The lancet respiratory medicine commission on the future of care of cystic fibrosis

SC Bell, MA Mall, H Gutierrez, M Macek… - The Lancet …, 2019 - pmc.ncbi.nlm.nih.gov
The past six decades have seen remarkable improvements in health outcomes for people
with cystic fibrosis (CF), which was once a fatal disease of infants and young children …

Infection prevention and control in cystic fibrosis: One size fits all The argument against

AR Smyth, SJ Smith, NJ Rowbotham - Paediatric Respiratory Reviews, 2020 - Elsevier
As awareness of the risks of cross infection has increased, infection prevention and control
measures have become more draconian. Infection control measures can have a profound …

[HTML][HTML] Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection

R Fischer, C Schwarz, R Weiser… - Journal of Cystic …, 2022 - Elsevier
OligoG has previously shown potentiation of aztreonam against Burkholderia cepacia
complex (Bcc) through biofilm disruption. A randomized, double-blind, placebo-controlled …